Encube Ethicals Ltd.
BSETBA
TBA
1 Shares
TBA
₹1
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 18,487 | 13,448 | |
| 631 | 242 | |
| 19,118 | 13,690 | |
| 11,848 | 9,118 | |
| 5,902 | 3,342 | |
| 4,367 | 2,496 |
Subscription Details
IPO Timeline
IPO Offer Start
TBA
IPO Offer Ends
TBA
TBA
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
80.91%
Promoter stake
About the Company
We are a global pharmaceutical formulations platform with deep domain expertise in technically complex topical and transdermal dosage forms, serving 50 countries including regulated markets such as the United States, UK and Europe, and India as of March 31, 2026. We operate through three business verticals: our global generics business (“Global Generics”), global contract development and manufacturing organization (“CDMO”) business (“Global CDMO”) and our India branded formulations business (“India Branded Formulations”), each serving different end markets and customer segments supported by a unified platform of R&D, manufacturing infrastructure, quality management systems and supply chain. The strength of this integrated platform is reflected across our market position, customer relationships and financial performance